Repligen Corp
$176.89
-$1.30 (-0.73%)
$176.29Day Range$179.10
Key Statistics
Market Cap
$10.06B
Shares Outstanding
56.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 29, 1986
Round Lot
100
Locale
US
Trading Data
Day Open
$179.10
Day High
$179.10
Day Low
$176.29
Volume
1.36M
VWAP
$177.40
Prev Close
$178.19
Transactions
--
Acc. Volume
--
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 28362,000 employees41 SEYON STREET, WALTHAM, MA, 02453(781) 449-9560IPO Apr 29, 1986US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000730272
- Composite FIGI
- BBG000BS48J3
- Share Class FIGI
- BBG001S5VNT9
- Ticker Root
- RGEN
- SIC Code
- 2836
About Repligen Corp (RGEN) Stock
Repligen Corp (RGEN) closed the 2026-09-18 session at $176.89, down 0.73% versus the previous close (-1.30). The stock opened at $179.10 and traded between $176.29 and $179.10 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $177.40.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Repligen Corp has a market capitalization of $10.06 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. RGEN is listed on the XNAS exchange. The company employs approximately 2,000 people. Repligen Corp is headquartered in WALTHAM, MA. The recorded listing date is 1986-04-29.
On this page you can find market RGEN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.